| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
The influence of finasteride on the development of prostate cancer.
|
N Engl J Med
|
2003
|
24.45
|
|
2
|
Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.
|
JAMA
|
2006
|
11.22
|
|
3
|
Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07.
|
J Clin Oncol
|
2007
|
7.73
|
|
4
|
Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.
|
J Natl Cancer Inst
|
2005
|
7.70
|
|
5
|
Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206.
|
J Clin Oncol
|
2008
|
6.23
|
|
6
|
Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer.
|
Cancer Prev Res (Phila)
|
2010
|
5.81
|
|
7
|
Prospective Validation of a 21-Gene Expression Assay in Breast Cancer.
|
N Engl J Med
|
2015
|
5.57
|
|
8
|
Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer.
|
N Engl J Med
|
2010
|
5.17
|
|
9
|
Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206.
|
J Clin Oncol
|
2010
|
5.08
|
|
10
|
Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08.
|
J Clin Oncol
|
2010
|
4.81
|
|
11
|
Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205.
|
J Clin Oncol
|
2010
|
4.69
|
|
12
|
Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer.
|
J Clin Oncol
|
2012
|
4.57
|
|
13
|
Bevacizumab added to neoadjuvant chemotherapy for breast cancer.
|
N Engl J Med
|
2012
|
4.10
|
|
14
|
Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer.
|
J Clin Oncol
|
2008
|
2.59
|
|
15
|
Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial.
|
Lancet Oncol
|
2013
|
2.59
|
|
16
|
Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial.
|
J Clin Oncol
|
2008
|
2.55
|
|
17
|
Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer.
|
J Clin Oncol
|
2009
|
2.34
|
|
18
|
Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B.
|
J Clin Oncol
|
2007
|
2.20
|
|
19
|
Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial.
|
J Clin Oncol
|
2013
|
2.12
|
|
20
|
Six cycles of doxorubicin and cyclophosphamide or Paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101.
|
J Clin Oncol
|
2012
|
2.07
|
|
21
|
Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5-hydroxytryptamine-3 antiemetics: a University of Rochester James P. Wilmot Cancer Center Community Clinical Oncology Program Study of 360 cancer patients treated in the community.
|
Cancer
|
2003
|
1.98
|
|
22
|
Phase III trial of fluorouracil-based chemotherapy regimens plus radiotherapy in postoperative adjuvant rectal cancer: GI INT 0144.
|
J Clin Oncol
|
2006
|
1.89
|
|
23
|
Prevalence of complementary and alternative medicine use in cancer patients during treatment.
|
Support Care Cancer
|
2005
|
1.76
|
|
24
|
Menstrual history and quality-of-life outcomes in women with node-positive breast cancer treated with adjuvant therapy on the NSABP B-30 trial.
|
J Clin Oncol
|
2011
|
1.56
|
|
25
|
Phase II study of high-dose fish oil capsules for patients with cancer-related cachexia.
|
Cancer
|
2004
|
1.56
|
|
26
|
Factor V Leiden mutation and thromboembolism risk in women receiving adjuvant tamoxifen for breast cancer.
|
J Natl Cancer Inst
|
2010
|
1.44
|
|
27
|
Bortezomib (PS-341) in relapsed or refractory extensive stage small cell lung cancer: a Southwest Oncology Group phase II trial (S0327).
|
J Thorac Oncol
|
2006
|
1.39
|
|
28
|
The efficacy of acupressure and acustimulation wrist bands for the relief of chemotherapy-induced nausea and vomiting. A University of Rochester Cancer Center Community Clinical Oncology Program multicenter study.
|
J Pain Symptom Manage
|
2003
|
1.13
|
|
29
|
Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101.
|
J Clin Oncol
|
2010
|
1.13
|
|
30
|
Results of the Southwest Oncology Group phase II evaluation (study S0031) of ZD1839 for advanced transitional cell carcinoma of the urothelium.
|
BJU Int
|
2009
|
1.11
|
|
31
|
Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced-stage non-small-cell lung cancer: Southwest Oncology Group study S0342.
|
J Clin Oncol
|
2010
|
1.06
|
|
32
|
Diagnostic microRNA markers to screen for sporadic human colon cancer in stool: I. Proof of principle.
|
Cancer Genomics Proteomics
|
2013
|
1.05
|
|
33
|
Treatment outcomes of different prognostic groups of patients on cancer and leukemia group B trial 39801: induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for unresectable stage III non-small cell lung cancer.
|
J Thorac Oncol
|
2009
|
1.04
|
|
34
|
Comparative effectiveness of sphincter-sparing surgery versus abdominoperineal resection in rectal cancer: patient-reported outcomes in National Surgical Adjuvant Breast and Bowel Project randomized trial R-04.
|
Ann Surg
|
2015
|
0.94
|
|
35
|
Exercise and side effects among 749 patients during and after treatment for cancer: a University of Rochester Cancer Center Community Clinical Oncology Program Study.
|
Support Care Cancer
|
2006
|
0.93
|
|
36
|
Racial disparities in traumatic stress in prostate cancer patients: secondary analysis of a National URCC CCOP Study of 317 men.
|
Support Care Cancer
|
2010
|
0.93
|
|
37
|
Diagnostic microRNA markers to screen for sporadic human colon cancer in blood.
|
Cancer Genomics Proteomics
|
2012
|
0.92
|
|
38
|
How do patient expectancies, quality of life, and postchemotherapy nausea interrelate?
|
Cancer
|
2008
|
0.89
|
|
39
|
Phase II evaluation of eribulin mesylate (E7389, NSC 707389) in patients with metastatic or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group trial S0618.
|
Invest New Drugs
|
2009
|
0.89
|
|
40
|
Evaluation of the combination of docetaxel/carboplatin in patients with metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN): a Southwest Oncology Group Phase II study.
|
Cancer Invest
|
2007
|
0.87
|
|
41
|
Phase II study of induction cisplatin and irinotecan followed by concurrent carboplatin, etoposide, and thoracic radiotherapy for limited-stage small-cell lung cancer, CALGB 30206.
|
J Thorac Oncol
|
2013
|
0.87
|
|
42
|
Higher doses of mitoxantrone among men with hormone-refractory prostate carcinoma: a Cancer and Leukemia Group B study.
|
Cancer
|
2002
|
0.86
|
|
43
|
Phase II study of carboplatin, irinotecan, and thalidomide in patients with advanced non-small cell lung cancer.
|
J Thorac Oncol
|
2006
|
0.84
|
|
44
|
The feasibility of adjuvant carboplatin and docetaxel in patients with curatively resected non-small cell lung cancer.
|
J Thorac Oncol
|
2008
|
0.84
|
|
45
|
Preliminary results of centralized HER2 testing in ductal carcinoma in situ (DCIS): NSABP B-43.
|
Breast Cancer Res Treat
|
2013
|
0.83
|
|
46
|
Assessment of quality of life and oral function of patients participating in a phase II study of radioprotection of oral and pharyngeal mucosa by the prostaglandin E(1) analog misoprostol (RTOG 96-07).
|
Int J Radiat Oncol Biol Phys
|
2002
|
0.80
|
|
47
|
Gemcitabine and irinotecan for patients with untreated extensive stage small cell lung cancer: SWOG 0119.
|
J Thorac Oncol
|
2007
|
0.79
|
|
48
|
Phase II trial of gemcitabine plus irinotecan in patients with esophageal cancer: a Southwest Oncology Group (SWOG) trial.
|
Am J Clin Oncol
|
2006
|
0.78
|
|
49
|
Split-course versus continuous thoracic radiation therapy for limited-stage small-cell lung cancer: final report of a randomized phase III trial.
|
Clin Lung Cancer
|
2005
|
0.77
|
|
50
|
Phase II trial of paclitaxel, carboplatin, and topotecan with G-CSF support in previously untreated patients with extensive stage small cell lung cancer: Southwest Oncology Group 9914.
|
J Thorac Oncol
|
2006
|
0.75
|
|
51
|
Cancer clinical trials in North Carolina.
|
N C Med J
|
2008
|
0.75
|